Metagenomi Therapeutics, Inc. MGX
0.61 USD -0.02 (-2.71%)
As ofNov 19, 2026, 3:49 PM EST
0.61 Day range 0.6423
0.60 52-week range 1.87
- YTD
- -62.06%
- 1 year
- -61.82%
Revenue & Expenses
Revenue Profit Costs
Latest period ending Dec 31, 2025 · select a line to chart its full history
Income statement
| Fiscal year | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| 25.21M | 52.30M | 44.76M | 17.20M | 243.00K | |
| 25.21M | 52.30M | 44.76M | 17.20M | 243.00K | |
| -96.01M | -88.90M | -78.49M | -44.64M | -23.95M | |
| -87.87M | -78.06M | -68.25M | -43.59M | -21.44M | |
| -2.36 | -2.36 | -20.05 | -12.82 | -6.58 |
Balance sheet
| Fiscal year | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| 46.91M | 32.63M | 145.85M | 190.51M | 43.40M | |
| 221.10M | 324.60M | 364.84M | 414.49M | 141.99M | |
| 62.51M | 89.74M | 149.67M | 142.81M | 98.04M | |
| 40.66M | 45.78M | 48.23M | 18.57M | 48.93M | |
| 158.60M | 234.86M | -135.58M | -74.43M | -32.54M |
Cash flow
| Fiscal year | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| -88.89M | -109.07M | -91.41M | 29.72M | 24.26M | |
| 103.53M | -88.16M | 45.73M | -122.20M | -74.32M | |
| -356.00K | 84.01M | 1.01M | 239.59M | 39.92M | |
| -537.00K | -3.11M | -9.81M | -13.98M | -2.90M | |
| 14.28M | -113.22M | -44.66M | 147.12M | -10.14M |
